ROIV is an outlier in its peer group right now: short interest at a year-high, the stock up 5.3% on the week, and options traders firmly in the bullish camp. That combination of rising shorts and rising price, without any squeeze pressure, is the central tension heading into Monday's earnings report. Among the closest mid-cap biotech peers, the week split sharply…
ROIV downgraded to Peer Perform from Outperform by Wolfe Research. Analyst Andy Chen cut rating today; consensus target stands at $48.08, implying 36% upside from $35.44.
Key data as of 11 Nov 2026
ROIV gained 5.3% over the past week, putting it at the top of a peer group that fell 0.7% at the median. Closest comparable IMVT added 4.7%, but CYTK dropped 14.8% and MLYS slid 15.7%, illustrating how sharply outcomes…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ROIV — free to start on ORTEX.
Sign up for free →Open ROIV on ORTEX